Phillips Wealth Planners LLC Buys 54 Shares of Stryker Co. (NYSE:SYK)

Phillips Wealth Planners LLC grew its stake in Stryker Co. (NYSE:SYK) by 8.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 701 shares of the medical technology company’s stock after acquiring an additional 54 shares during the quarter. Phillips Wealth Planners LLC’s holdings in Stryker were worth $253,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in SYK. Patrick M Sweeney & Associates Inc. boosted its stake in shares of Stryker by 1.5% in the third quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company’s stock worth $793,000 after acquiring an additional 32 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in shares of Stryker by 2.4% during the first quarter. Proficio Capital Partners LLC now owns 1,418 shares of the medical technology company’s stock worth $507,000 after buying an additional 33 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Stryker by 4.0% in the second quarter. Versant Capital Management Inc now owns 864 shares of the medical technology company’s stock worth $294,000 after buying an additional 33 shares in the last quarter. Stanley Laman Group Ltd. boosted its position in Stryker by 4.6% during the second quarter. Stanley Laman Group Ltd. now owns 752 shares of the medical technology company’s stock worth $256,000 after acquiring an additional 33 shares during the last quarter. Finally, Plimoth Trust Co. LLC grew its stake in Stryker by 0.3% during the 2nd quarter. Plimoth Trust Co. LLC now owns 9,476 shares of the medical technology company’s stock valued at $3,224,000 after acquiring an additional 33 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

SYK stock opened at $367.15 on Friday. The business’s fifty day moving average price is $360.18 and its 200 day moving average price is $344.26. Stryker Co. has a 12-month low of $266.93 and a 12-month high of $374.63. The company has a current ratio of 1.91, a quick ratio of 0.95 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $139.96 billion, a PE ratio of 39.35, a P/E/G ratio of 2.69 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the prior year, the firm earned $2.46 earnings per share. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Stryker Co. will post 12.06 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.80 dividend. The ex-dividend date was Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is presently 34.30%.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Stryker news, Director Ronda E. Stryker sold 190,000 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total value of $61,457,400.00. Following the sale, the director now directly owns 3,316,608 shares in the company, valued at $1,072,790,023.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 200,068 shares of company stock worth $65,151,372 in the last quarter. 5.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on SYK shares. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. Evercore ISI lifted their price objective on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday. Wells Fargo & Company upped their target price on Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a report on Wednesday. Royal Bank of Canada lifted their price target on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, BTIG Research upped their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $393.65.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.